Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,189,918
  • Shares Outstanding, K 103,298
  • Annual Sales, $ 158,180 K
  • Annual Income, $ -107,320 K
  • EBIT $ -128 M
  • EBITDA $ -124 M
  • 60-Month Beta -1.25
  • Price/Sales 8.35
  • Price/Cash Flow N/A
  • Price/Book 3.00

Options Overview Details

View History
  • Implied Volatility 11.73% (-103.26%)
  • Historical Volatility 170.52%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 613.84% on 10/23/25
  • IV Low 11.73% on 03/06/26
  • Expected Move (DTE 13) 0.42 (1.96%)
  • Put/Call Vol Ratio 0.75
  • Today's Volume 46,776
  • Volume Avg (30-Day) 3,680
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 48,388
  • Open Int (30-Day) 49,814
  • Expected Range 20.78 to 21.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.30
  • Number of Estimates 7
  • High Estimate -0.09
  • Low Estimate -1.04
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.97 +112.64%
on 03/03/26
21.23 -0.14%
on 03/06/26
+9.79 (+85.80%)
since 02/06/26
3-Month
7.90 +168.35%
on 12/08/25
21.23 -0.14%
on 03/06/26
+13.28 (+167.68%)
since 12/05/25
52-Week
5.64 +276.22%
on 08/06/25
21.23 -0.14%
on 03/06/26
+12.10 (+132.97%)
since 03/06/25

Most Recent Stories

More News
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals...

DAWN : 21.20 (+65.88%)
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , March 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Day One (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

DAWN : 21.20 (+65.88%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)

NEW YORK , March 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions...

DAWN : 21.20 (+65.88%)
DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

DAWN : 21.20 (+65.88%)
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

SURESNES, France and BRISBANE, Calif. , March 6, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq:...

DAWN : 21.20 (+65.88%)
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

SURESNES, France and BRISBANE, Calif. , March 6, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN)...

DAWN : 21.20 (+65.88%)
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total...

DAWN : 21.20 (+65.88%)
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded...

DAWN : 21.20 (+65.88%)
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 21.20 (+65.88%)
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate...

DAWN : 21.20 (+65.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One Biopharmaceuticals Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 21.41
2nd Resistance Point 21.32
1st Resistance Point 21.26
Last Price 21.20
1st Support Level 21.11
2nd Support Level 21.02
3rd Support Level 20.96

See More

52-Week High 21.23
Last Price 21.20
Fibonacci 61.8% 15.27
Fibonacci 50% 13.43
Fibonacci 38.2% 11.59
52-Week Low 5.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar